Suchitra Sundaram, MD, reflects on a patient experience early in her career that exemplified the lack of therapeutic options for mantle cell lymphoma (MCL) available at that time. Since then, as Dr Sundaram notes, the advent of targeted and immunotherapies has made it possible for patients to achieve lasting disease control and remission without disturbing their daily lives.
Dr Sundaram also points to the recent approval of CAR T-cell immunotherapies available for patients with MCL as providing another option for patients who have progressed past one or two lines of therapy, though these treatments require an inpatient setting. Looking ahead, she also considers the possible revolutionary addition of bispecific antibodies, which can be delivered in an outpatient setting, as a potential option to treat patients in a way that fits their daily lives.
Medscape © 2023 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: A Patient Experience That Illustrates the Changing Treatment Landscape in Mantle Cell Lymphoma - Medscape - Jan 19, 2023.